https://www.marketscreener.com/quote/stock/CELLECT-BIOTECHNOLOGY-LTD-23145597/news/Cellect-Biotechnology-First-Cancer-Patient-Treated-In-Phase-I-II-Trial-Management-expects-addition-23897256/?utm_source=telegram&utm_medium=social&utm_campaign=share